🏆 Deal of the Week · CW 37/2024
PanTera raised EUR 93 million in a Series A funding round; valuation remains undisclosed. EQT Life Sciences led the round, joined by a syndicate of seven co-investors. The capital will support construction of PanTera's Ac-225 production facility in Mol, Belgium.
PanTera — key deal facts
| Company | PanTera |
| Founded | 2022 |
| Headquarters | Mol, Belgium |
| Amount raised | EUR 93m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | EQT Life Sciences, Eurazeo, Ion Beam Applications, Korys, Kurma Partners, Paladin, PMV, SFPIM |
| Sectors | Health Care |
Who invested in PanTera?
The round drew participation from EQT Life Sciences, Eurazeo, Ion Beam Applications, Korys, Kurma Partners, Paladin, PMV, and SFPIM. The investor mix is notable for combining a global life-sciences growth fund with Belgian public and industrial stakeholders, reflecting both strategic and national-interest backing. The presence of Ion Beam Applications as a financial investor is significant, given its role as a co-founding shareholder alongside SCK CEN.
What does PanTera do?
PanTera is a Belgian radiopharmaceutical company focused on the production of actinium-225 (Ac-225), a radioactive isotope used as an active pharmaceutical ingredient in targeted cancer therapies. The company's work sits at the intersection of radiotheranostics and precision oncology, supplying high-purity Ac-225 to support next-generation treatments for cancer and other serious illnesses. PanTera was founded in 2022 as a joint venture between Ion Beam Applications (IBA) and the Belgian Nuclear Research Centre (SCK CEN), and is headquartered in Mol, Belgium, where it is constructing a dedicated Ac-225 production facility.
PanTera valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did PanTera raise in its Series A?
PanTera raised EUR 93 million in a Series A round, announced in September 2024.
What is PanTera's valuation?
PanTera's post-money valuation was not disclosed as part of this transaction.
Who invested in PanTera?
The Series A was led by EQT Life Sciences, with co-investors Eurazeo, Ion Beam Applications, Korys, Kurma Partners, Paladin, PMV, and SFPIM.
When was PanTera founded and where is it based?
PanTera was founded in 2022 and is headquartered in Mol, Belgium.
Source: original announcement — read the full report.